DadFinStart your free week
DadFin › Stocks › Healthcare › KNSA

Kiniksa Pharmaceuticals Internatio (KNSA) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United Kingdom

$79.78 ▲ +1.31% today

59.1
Dad Score, out of 100
middling

Kiniksa Pharmaceuticals Internatio (KNSA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United Kingdom. On DadFin's weekly run it scores 59.1 out of 100 on the Dad Score, a middling reading that places the business ahead of 59% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #340 of 974. Its strongest axes are growth, risk and conviction.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Average
Growth
Above average
Price action
Average
Risk
Strong
Conviction
Above average
Liquidity
Above average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)76.6×
P/E (forward)46.9×
Dividend yield0.00%
Return on capital14.2%
Operating margin11.2%
Revenue growth (YoY)+60.1%
FCF yield2.4%
Net debt / EBITDA-5.07×
Piotroski F-Score6 / 9
52-week change+97.9%
Market cap$5.8B
Next earningsOct 27, 2026

What subscribers see on KNSA

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.